Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
OncoSTING Logo
OncoSTING Growth Score
34
CB Rank
175614
Heat Score
40
OncoSTING is developing novel bladder cancer therapies by harnessing the potency of standard BCG immunotherapy
Founded
obfuscation
PrivateGrant Baltimore, Maryland, United States1-10 www.oncosting.com
Health Care
Overview

OncoSTING
Total Funding
obfuscation
Growth Score
34
Heat Score
40

Total Funding
obfuscation
obfuscation
Grant raised
obfuscation
Growth Score34
-4 pts
in past quarter
Heat Score 40
-19 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About OncoSTING

CB Rank
175614
OncoSTING is developing novel bladder cancer therapies by harnessing the potency of standard BCG immunotherapy
Founded
obfuscation
PrivateGrant Baltimore, Maryland, United States1-10 www.oncosting.com
Health Care

Funding Rounds

Grant
OBF
in
obfuscation
Grant
OBF
in
obfuscation

Key People

Details

Legal Name OncoSTING LLC
Operating Status Active
Company Type For Profit
Founders  Bill Bishai, Trinity Bivalacqua
About the Company
OncoSTING, located in Baltimore, is developing novel bladder cancer therapies that work by combining the potency of standard BCG immunotherapy with long-lived delivery of potent STING agonists. (JHU)
Contact Email info@OncoSTING.com
Predictions & Insights

Growth Prediction

See this Growth Prediction

Products & Services

OS-151
A second-generation BCG immunotherapy for bladder cancer that produces high levels of a potent STING agonist while retaining the known efficacy of traditional BCG. It is also being developed as an intratumoral immunotherapy for certain solid tumors.

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials

Company Funding

Total Funding Amount 
obfuscation
Number of Funding Rounds 2
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Grant - OncoSTING Logo
Grant - OncoSTING
1
obfuscation
— Grant
obfuscation
Grant - OncoSTING Logo
Grant - OncoSTING
1
obfuscation
— Grant
obfuscation
Grant - OncoSTING Logo
Grant - OncoSTING
1
obfuscation
— Grant
obfuscation
Grant - OncoSTING Logo
Grant - OncoSTING
1
obfuscation
— Grant
obfuscation
Grant - OncoSTING Logo
Grant - OncoSTING
1
obfuscation
— Grant

Funding Rounds

Total Funding Amount 
obfuscation
Number of Funding Rounds 2
Unlock company funding data, including rounds, dates, amounts, and investors.
Announced Date  
Transaction Name  
Number of Investors  
Money Raised  
Lead Investors  
Funding Type  
obfuscation
Grant - OncoSTING Logo
Grant - OncoSTING
1
obfuscation
— Grant
obfuscation
Grant - OncoSTING Logo
Grant - OncoSTING
1
obfuscation
— Grant
obfuscation
Grant - OncoSTING Logo
Grant - OncoSTING
1
obfuscation
— Grant
obfuscation
Grant - OncoSTING Logo
Grant - OncoSTING
1
obfuscation
— Grant
obfuscation
Grant - OncoSTING Logo
Grant - OncoSTING
1
obfuscation
— Grant

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.
Investor Name  
Lead Investor  
Funding Round  
Partners  
National Science Foundation Logo
National Science Foundation
—
Grant - OncoSTING Logo
Grant - OncoSTING
—
National Science Foundation Logo
National Science Foundation
—
Grant - OncoSTING Logo
Grant - OncoSTING
—
National Science Foundation Logo
National Science Foundation
—
Grant - OncoSTING Logo
Grant - OncoSTING
—
National Science Foundation Logo
National Science Foundation
—
Grant - OncoSTING Logo
Grant - OncoSTING
—
National Science Foundation Logo
National Science Foundation
—
Grant - OncoSTING Logo
Grant - OncoSTING
—
Market Intelligence
People
View Profiles & Contacts
Headcount 1-10 Employee Profiles 3

Employee Profiles

News
Technology
View Tech Report

IT Spend

$73.9KThis year, OncoSTING is projected to spend $73.9K on IT, according to Aberdeen.

Active Website Tech Count

4OncoSTING is actively using 4 technologies for its website, according to BuiltWith. These include Viewport Meta, CommonCrawl Top 50m, and  Euro.
Sub-Organizations
Frequently Asked Questions

Where is OncoSTING's headquarters? OncoSTING is located in Baltimore, Maryland, United States.Who invested in OncoSTING? OncoSTING has 2 investors including National Science Foundation and  Maryland Innovation Initiative (MII).When was the last funding round for OncoSTING? OncoSTING closed its last funding round on
obfuscation
from a Grant round.How much funding has OncoSTING raised to date? OncoSTING has raised
obfuscation
.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(9fd75b2 1)
|